Caicun Zhou

18PUBLICATIONS
85CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Nov 06, 2026
PADL1NK-005 study design: a phase III trial of fetrastobart vedotin (Fetra-V) vs docetaxel in patients with previously treated tumor PD-L1-positive NSCLC.

|Oct 13, 2026
Camrelizumab plus chemotherapy as induction therapy followed by concurrent chemoradiotherapy and camrelizumab consolidation in limited-stage small cell lung cancer: a randomized phase II trial.

|Sep 07, 2026
Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer.

|Aug 12, 2026
Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study.

|Dec 01, 2025
Phase 1b Multicenter Study of SG001, a Humanized Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors.

Jian Fang, Ou Jiang, Wei Li

|Nov 14, 2025
Cost-effectiveness of PD-L1 testing to guide immunotherapy for patients with advanced non-small-cell lung cancer in China.

Fei Zhou, Yuan Li, Jian Ming

Pageof 3

Frequent Collaborators

4 joint publications

Fei Zhou

2 joint publications

Ying Cheng

2 joint publications

Yongqian Shu

2 joint publications

Fengying Wu